Guidance

Prostate cancer risk management programme: PSA test benefits and risks

This publication is to help GPs give asymptomatic men information about the potential benefits and risks of PSA testing for prostate cancer.

• From: Public Health England
• Published: 29 March 2016

This publication was withdrawn on 27 July 2021

This guidance is out of date. Please refer to Prostate cancer risk management programme: overview.

Documents

[Withdrawn] Prostate cancer risk management programme (PCRMP): benefits and risks of PSA testing

HTML

Details

The Prostate cancer risk management programme (PCRMP) aims to help primary care give clear and balanced information to asymptomatic men who ask about testing for prostate cancer.

The prostate specific antigen (PSA) test is available free to any man aged 50 or over who requests it, after careful consideration of the implications.

Men concerned about the risk of prostate cancer should receive clear and balanced information about the advantages and disadvantages of the PSA test, biopsy and treatments for prostate cancer. This means men can make informed decisions about whether or not to have a PSA test.

Published 29 March 2016